Needham & Company Upgrades BioCryst Pharma (BCRX) to Buy, 'Pipeline Setback Provides Attractive Entry Opportunity'
Tweet Send to a Friend
(Updated - February 22, 2023 7:17 AM EST)
Needham & Company analyst Serge Belanger upgraded BioCryst Pharma (NASDAQ: BCRX) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Needham & Company analyst Serge Belanger upgraded BioCryst Pharma (NASDAQ: BCRX) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
